This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up

Menu

Close

About CIBINQOEfficacyEfficacyOverviewEfficacy of CIBINQO + Medicated TopicalsEfficacy of CIBINQO Without Medicated TopicalsReduction in Risk of FlaresLong-term Efficacy ResultsBefore and After PhotosGlossarySafetySafetySafety ProfileSafety ConsiderationsLab AbnormalitiesDosing & MonitoringDosing &
MonitoringDosingLab Monitoring

Click here for CIBINQO Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
CIBINQO (abrocitinib)▼ - a once-daily oral JAK1 inhibitor for moderate-to-severe atopic dermatitis (AD)1

Cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.1

 Whether your patients’ moderate-to-severe AD is FIERCE or TAMER. 

Take it on with CIBINQO About CibinqoLoading Take On the Variability of Moderate-to-Severe AD

CIBINQO has been extensively studied in 7 phase 3 trials, including 1 ongoing long-term extension study evaluating safety and efficacy in patients with moderate-to-severe AD2

 See the Efficacy Overview Loading The Convenience of a Once-daily Oral Option

CIBINQO offers flexibility so you can tailor treatment to meet the individual needs of your patients

 Go to Dosing Loading See patient results with CIBINQO in the JADE clinical program

View images of patients with moderate-to-severe AD from the JADE clinical trials.

 Before and After Photos Loading Safety Across Clinical Trials

Consistent safety profile in patients with moderate-to severe AD studied across JADE clinical trials 

 See Safety Profile LoadingGetting Started With CIBINQO

A quick reference guide that outlines what you need to know about starting patients on CIBINQO

 Download Loading
See patient results with CIBINQO in the JADE clinical program10​​ Before and After Photos Loading Safety Across Clinical Trials

Consistent safety profile with >3100 adults and adolescents studied across JADE clinical trials2-6,11,12

 See Safety Profile Loading Have a Product Question? Request an eRep Call Loading
JAK=Janus kinase; AD=atopic dermatitisPrescribing information
Please see the CIBINQO Summary of Product Characteristics for more information.Although some clinical trials included adolescents, please note that CIBINQO is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.References:CIBINQO Summary of Product Characteristics.Simpson EL, Silverberg JI, Nosbaum A, et al. Safety of abrocitinib in 3582 patients with moderate-to-severe atopic dermatitis with over 900 patients exposed for almost 2 years. Poster P0362. Presented at: European Academy of Dermatology and Venereology Hybrid Congress; 7–10 September 2022.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.

Legal Category: S1A
Further information is available upon request

PP-CIB-IRL-0085 May 2023

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.

 

Copyright © 2023 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0176. January 2023
For Healthcare Professionals in the Republic of Ireland *

The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.

I confirm that I am a healthcare professional resident in the Republic of Ireland.*

I accept and agree to the terms of use.*

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.

PP-UNP-IRL-0176. January 2023

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.